Endoscopy, morphology, morphometry and molecular markers: Predicting cancer risk in colorectal adenoma

Expert Review of Molecular Diagnostics

Volumn 9, Issue 2, 2009, Pages 125-137

  Soøreide, Kjetil ^a   Nedreboø, Bjoørn S ^a   Reite, Andreas ^a   Thorsen, Kenneth ^a   Koørner, Hartwig ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Biomarker; Cancer; Colorectal adenoma; Diagnostics; Endoscopy; Genetic instability; Genomic; Histology; Molecular technology; Pathology; Proteomic; Risk

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CHROMOENDOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; ENDOCYTOSCOPY; ENDOSCOPIC POLYPECTOMY; HISTOPATHOLOGY; HUMAN; LARGE INTESTINE CANCER; MICROSCOPY; MORPHOMETRICS; PREVALENCE; REVIEW; ADENOMA; COLORECTAL TUMOR; ENDOSCOPY; METABOLISM; METHODOLOGY; PATHOLOGY; RISK FACTOR;

ADENOMA; COLORECTAL NEOPLASMS; ENDOSCOPY; HUMANS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 66549090189     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.2.125     Document Type: Review

References (91)

1. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007).
2. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1), 113-130 (2007).
3. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br. J. Surg. 93(4), 395-406 (2006).
4. Kudo S, Kashida H, Tamura T et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. WorldJ. Surg. 24(9), 1081-1090 (2000).
5. Kudo S, Kashida H, Nakajima T, Tamura S, Nakajo K. Endoscopic diagnosis and treatment of early colorectal cancer. World J. Surg. 21(7), 694-701 (1997).
6. Kudo S, Kashida H, Tamura S, Nakajima T. The problem of "flat" colonic adenoma. Gastrointest. Endosc. Clin. N. Am. 7(1), 87-98 (1997).
7. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy 25(7), 455-461 (1993).
8. Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest. Endosc. Clin. N. Am. 7(3), 387-399 (1997).
9. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand. J. Gastroenterol. 38(6), 635 -642 (2003).
10. Giacosa A, Frascio F, Munizzi F. Epidemiology of colorectal polyps. Tech. Coloproctol. (Suppl. 2), S243-S247 (2004).
11. Paillot B, Czernichow P, Michel P et al. Incidence of rectosigmoid adenomatous polyps in subjects without prior colorectal adenoma or cancer: a prospective cohort study. Gut 44(3), 372-376 (1999).
12. Neugut AI, Jacobson JS, De Vivo I. Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol. Biomarkers Prev. 2(2), 159-176 (1993).
13. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 135(2), 380-399 (2008).
14. Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin. Cancer Res. 12(12), 3661-3697 (2006).
15. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin. Cancer Res. 7(5), 1118-1126 (2001).
16. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg. Oncol. 18(1), 31-50 (2009).
17. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 89(2), 328-336 (1985).
18. Kashida H, Kudo SE. Early colorectal cancer: concept, diagnosis, and management. Int. J. Clin. Oncol. 11(1), 1-8 (2006).
19. de Graaf EJ. Transanal endoscopic microsurger y. Scand. J. Gastroenterol. Suppl. (239), 34-39 (2003).
20. Ganai S, Kanumuri P, Rao RS, Alexander AI. Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. Ann. Surg. Oncol. 13(4), 547-556 (2006).
21. Guerrieri M, Baldarelli M, Morino M et al. Transanal endoscopic microsurgery in rectal adenomas: experience of six Italian centres. Dig. LiverDis. 38(3), 202-207 (2006).
22. Middleton PF, Sutherland LM, Maddern GJ. Transanal endoscopic microsurgery: a systematic review. Dis. Colon. Rectum 48(2), 270-284 (2005).
23. Smith LA, Tiffin N, Thomson M, Cross SS, Hurlstone DP. Chromoscopic endomicroscopy: in vivo cellular resolution imaging of the colorectum. J. Gastroenterol. Hepatol. 23(7 Pt 1), 1009-1023 (2008).
24. Meroni E, Gatteschi B, Fasoli A et al. Detection of tissue abnormalities in normal mucosa surrounding colorectal cancer using an endocytoscopy system. Endoscopy 39(4), 369-370 (2007).
25. Sasajima K, Kudo SE, Inoue H et al. Real-time in vivo virtual histology of colorectal lesions when using the endocytoscopy system. Gastrointest. Endosc. 63(7), 1010-1017 (2006).
26. Kodashima S, Fujishiro M, Takubo K et al. Ex-vivo study of high-magnification chromoendoscopy in the gastrointestinal tract to determine the optimal staining conditions for endocytoscopy. Endoscopy 38(11), 1115-1121 (2006).
27. Kudo S, Kashida H, Tamura T. Early colorectal cancer: flat or depressed type. J. Gastroenterol. Hepatol. 15(Suppl.), D66-D70 (2000).
28. Kumagai Y, Monma K, Kawada K. Magnifying chromoendoscopy of the esophagus: in-vivo pathological diagnosis using an endocytoscopy system. Endoscopy 36(7), 590-594 (2004).
29. Kudo S, Hirota S, Nakajima T et al. Colorectal tumours and pit pattern. J. Clin. Pathol. 47(10), 880-885 (1994).
30. Kudo S, Tamura S, Nakajima T, Yamano H, Kusaka H, Watanabe H. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest. Endosc. 44(1), 8-14 (1996).
31. Poppers DM, Haber GB. Endoscopic mucosal resection of colonic lesions: current applications and future prospects. Med. Clin. North Am. 92(3), 687-705, (2008).
32. Hurlstone DP, Fu KI, Brown SR et al. EMR using dextrose solution versus sodium hyaluronate for colorectal Paris type I and 0-II lesions: a randomized endoscopist- blinded study. Endoscopy 40(2), 110-114 (2008).
33. Hurlstone DP. The detection of flat and depressed colorectal lesions: which endoscopic imaging approach? Gastroenterol. 135(2), 338-343 (2008).
34. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Three randomized long-term surveillance trials in patients with sporadic colorectal adenomas. Scand. J. Gastroenterol. 41(6), 737-743 (2006).
35. Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N. Engl. J. Med. 359(12), 1218-1224 (2008).
36. Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterol. 130(6), 1872-1885 (2006).
37. Saini SD, Kim HM, Schoenfeld P. Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a meta-analysis and systematic review. Gastrointest. Endosc. 64(4), 614-626 (2006).
38. Robertson DJ, Greenberg ER, Beach M et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterol. 129(1), 34-41 (2005).
39. Loeve F, van Ballegooijen M, Boer R, Kuipers EJ, Habbema JD. Colorectal cancer risk in adenoma patients: a nation-wide study. Int. J. Cancer 111(1), 147-151 (2004).
40. Terry MB, Neugut AI, Bostick RM, Potter JD, Haile RW, Fenoglio-Preiser CM. Reliability in the classification of advanced colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 11(7), 660-663 (2002).
41. Bedenne L, Faivre J, Boutron MC, Piard F, Cauvin JM, Hillon P. Adenoma-carcinoma sequence or "de novo" carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers. Cancer 69(4), 883-888 (1992).
42. Kudo S, Tamura S, Hirota S et al. The problem of de novo colorectal carcinoma. Eur. J. Cancer 31A(7-8), 1118-1120 (1995).
43. Shimoda T, Ikegami M, Fujisaki J, Matsui T, Aizawa S, Ishikawa E. Early colorectal carcinoma with special reference to its development de novo. Cancer 64(5), 1138-1146 (1989).
44. Hermanek P, Gall FP. Early (microinvasive) colorectal carcinoma. Pathology, diagnosis, surgical treatment. Int. J. Colorectal Dis. 1(2), 79-84 (1986).
45. Mueller JD, Bethke B, Stolte M. Colorectal de novo carcinoma: a review of its diagnosis, histopathology, molecular biology, and clinical relevance. Virchows Arch. 440(5), 453-460 (2002).
46. Muto T, Nagawa H, Watanabe T, Masaki T, Sawada T. Colorectal carcinogenesis: historical review. Dis. Colon. Rectum 40(10 Suppl.), S80-S85 (1997).
47. Alrawi SJ, Schiff M, Carroll RE et al. Aberrant crypt foci. Anticancer. Res. 26(1A), 107-119 (2006).
48. Takayama T, Katsuki S, Takahashi Y et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339(18), 1277-1284 (1998).
49. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin. Gastroenterol. Hepatol. 5(5), 526-533 (2007).
50. Glebov OK, Rodriguez LM, Soballe P et al. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol. Biomarkers Prev. 15(11), 2253-2262 (2006).
51. Schoen RE, Mutch M, Rall C et al. The natural history of aberrant crypt foci. Gastrointest. Endosc. 67(7), 1097-1102 (2008).
52. Kariya J, Mizuno K, Mayama M. A case of early colorectal cancer type IIc associated with familial polyposis coli. [Japanese with English abstract] Stomach Intestine 12, 1359-1364 (1977).
53. Tsuda S, Veress B, Toth E, Fork FT. Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study. Gut 51(4), 550-555 (2002).
54. Hamilton SR, Vogelstein B, Kudo S et al. Carcinoma of the colon and rectum. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours oof the Digestive System. Hamilton SR, Aaltonen LA (Eds.) IACR Press, Lyon, France (2000).
55. Schlemper RJ, Itabashi M, Kato Y et al. Differences in the diagnostic criteria used by Japanese and Western pathologists to diagnose colorectal carcinoma. Cancer 82(1), 60-69 (1998).
56. Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47(2), 251-255 (2000).
57. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. Biopsy of colorectal polyps is not adequate for grading of neoplasia. Endoscopy 37(12), 1193-1197 (2005).
58. Kulling D, Christ AD, Karaaslan N, Fried M, Bauerfeind P. Is histological investigation of polyps always necessary? Endoscopy 33(5), 428-432 (2001).
59. Eide TJ, Nielsen K, Solberg S. Dysplasia in colorectal adenomas related to the presence of O -acylated sialic mucin and to morphometric measurements. Acta Pathol. Microbiol. Immunol. Scand. [A]95(6), 365-369 (1987).
60. Hamilton PW, Thompson D, Sloan JM, Bartels PH. Knowledge-guided segmentation and morphometric analysis of colorectal dysplasia. Anal. Quant. Cytol. Histol. 17(3), 172-182 (1995).
61. Meijer GA, Fleege JC, Baak JP. Stereological assessment of architectural changes in dysplastic epithelium of colorectal adenomas. Pathol. Res. Pract. 190(4), 333-341 (1994).
62. Meijer GA, van Diest PJ, Fleege JC, Baak JP. Syntactic structure analysis of the arrangement of nuclei in dysplastic epithelium of colorectal adenomatous polyps. Anal. Quant. Cytol. Histol. 14(6), 491-498 (1992).
63. Mulder JW, Offerhaus GJ, de Feyter EP et al. The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am. J. Pathol. 141(4), 797-804 (1992).
64. Hoff G, Clausen OP, Fjordvang H, Norheim A, Foerster A, Vatn MH. Epidemiology of polyps in the rectum and sigmoid colon. Size, enzyme levels, DNA distributions, and nuclear diameter in polyps of the large intestine. Scand. J. Gastroenterol. 20(8), 983-989 (1985).
65. Eide TJ. A morphometrical analysis of dysplasia in small adenomas of the large intestine. Virchows Arch. A Pathol. Anat. Histopathol. 410(2), 119-124 (1986).
66. S0reide K, Buter TC, Janssen EA, van Diermen B, Baak JP. A monotonous population of elongated cells (MPECs) in colorectal adenoma indicates a high risk of metachronous cancer. Am. J. Surg. Pathol. 30(9), 1120-1129 (2006).
67. Soreide K, Buter TC, Janssen EA et al. Cell-cycle and apoptosis regulators (p16INK4A, p21CIP1, beta-catenin, survivin, and hTERT) and morphometry- defined MPECs predict metachronous cancer development in colorectal adenoma patients. Cell Oncol. 29(4), 301-313 (2007).
68. Soreide K, Gudlaugsson E, Skaland I et al. Metachronous cancer development in patients with sporadic colorectal adenomas - multivariate risk model with independent and combined value of hTERT and survivin. Int. J. Colorectal. Dis. 23(4), 389-400 (2008).
69. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158(2), 527-535 (2001).
70. Meijer GA, Meuwissen SG, Baak JP. Classification of colorectal adenomas with quantitative pathology. Evaluation of morphometry, stereology, mitotic counts and syntactic structure analysis. Anal. Cell. Pathol. 9(4), 311-323 (1995).
71. Meijer GA, Baak JP. Cytonuclear morphometry in the assessment of dysplasia in colorectal adenomatous polyps. A pilot study. Pathol. Res. Pract. 188(1-2), 148-156 (1992).
72. Meijer GA, Baak JP, Talbot IC, Atkin WS, Meuwissen SG. Predicting the risk of metachronous colorectal cancer in patients with rectosigmoid adenoma using quantitative pathological features. A case-control study. J. Pathol. 184(1), 63-70 (1998).
73. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg. Oncol. DOI: 10.1016/j.suronc.2008.06.006 (2008) (Epub ahead of print).
74. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
75. Soreide K. Telomerase and survivin in colorectal and pancreatic cancer - biomarkers of life and death in the balance between proliferation and apoptosis. Curr. Cancer Ther. Rev. 4(4), 253-261 (2008).
76. Soreide K, Janssen EA, Korner H, Baak JP. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J. Pathol. 209(2), 147-156 (2006).
77. Soreide K, Thorsen K. Colorectal cancer - increased understanding of the multidimensional molecular genesis. Curr. Cancer Ther. Rev. 4(4), 243-252 (2008).
78. Smith G, Carey FA, Beattie J et al. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc. Natl Acad. Sci. USA 99(14), 9433-9438 (2002).
79. Leslie A, Pratt NR, Gillespie K et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 63(15), 4656-4661 (2003).
80. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54(9), 1283-1286 (2005).
81. Ransohoff DF, Martin C, Wiggins WS et al. Assessment of serum proteomics to detect large colon adenomas. Cancer Epidemiol. Biomarkers Prev. 17(8), 2188-2193 (2008).
82. Han M, Liew CT, Zhang HW et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res. 14(2), 455-460 (2008).
83. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 16(10), 1935-1953 (2007).
84. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23(36), 9067-9072 (2005).
85. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001).
86. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J. Clin. Pathol. 62(1), 1-5 (2009).
87. Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin. Cancer Res. 13(22 Pt 2), 6871S-6876S (2007).
88. Soreide K, Slewa A, Stokkeland PJ et al. Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection. Cancer 115(2), 271-282 (2009).
89. Soreide K. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers - ready for prime time? Tumour Biol. 28(5), 290-300 (2007).
90. Wallace MB. Improving colorectal adenoma detection: technology or technique? Gastroenterol. 132(4), 1221-1223 (2007).
91. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 60(12), 1205-1